1. Bartsch, H. (1996) DNA adducts in human carcinogenesis: etiological relevance and structure-activity relationship. Mutat. Res., in press.
2. Alexandrov, K, Rojas, M., Geneste, O., Castegnaro, M., Camus, AM., Petruzzelli, S., Giuntini, C. and Bartsch, H. (1992) An improved fluorometric assay for dosimetry of benzo[a]pyrene diol-epoxide-DNA adducts in smokers’ lung: comparisons with total bulky adducts and AHH activity, Cancer Res., 52, 6248–6253.
3. Rojas, M., Alexandrov, K., van Schooten, F.J., Hillebrand, M., Kriek, E. and Bartsch, H. (1994) Validation of a new fluorometric assay for benzo[a]pyrene diolepoxide-DNA adducts in human white blood cells: comparisons with 32P-postlabelling and ELISA. Carcinogenesis, 15, 557–560.
4. Anttila, S., Hietanen, E., Vainio, H., Camus, A-M., Gelboin, H.V., Park, S.S., Heikkilâ, L., Karjalainen, A and Bartsch, H. (1991) Smoking and peripheral type of cancer are related to high levels of pulmonary cytochrome P450–1A1 in lung cancer patients, Int. J. Cancer, 47, 681–685.
5. Hirvonen, A., Husgafvel-Pursiainen, K., Anttila, S. and Vainio, H. (1993) The GSTM1 null genotype as a potential risk modifier for squamous cell carcinoma of the lung. Carcinogenesis, 14, 1479–1481.